87 related articles for article (PubMed ID: 16133107)
1. Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice.
Ribas A; Vo DD; Weeks DL; Comin-Anduix B; Schumacher LY; Garban HJ; McLean C; Yang J; Dissette VB; Peraza P; Owens SK; McBride WH; Glaspy JA; Economou JS
Cancer Immunol Immunother; 2006 Jun; 55(6):663-71. PubMed ID: 16133107
[TBL] [Abstract][Full Text] [Related]
2. Poly I:C-induced activation of NK cells by CD8 alpha+ dendritic cells via the IPS-1 and TRIF-dependent pathways.
Miyake T; Kumagai Y; Kato H; Guo Z; Matsushita K; Satoh T; Kawagoe T; Kumar H; Jang MH; Kawai T; Tani T; Takeuchi O; Akira S
J Immunol; 2009 Aug; 183(4):2522-8. PubMed ID: 19635904
[TBL] [Abstract][Full Text] [Related]
3. Anatomic location defines antigen presentation by dendritic cells to T cells in response to intravenous soluble antigens.
Chung Y; Chang JH; Kim BS; Lee JM; Kim HY; Kang CY
Eur J Immunol; 2007 Jun; 37(6):1453-62. PubMed ID: 17474148
[TBL] [Abstract][Full Text] [Related]
4. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
5. DC therapy induces long-term NK reactivity to tumors via host DC.
Shimizu K; Fujii S
Eur J Immunol; 2009 Feb; 39(2):457-68. PubMed ID: 19180466
[TBL] [Abstract][Full Text] [Related]
6. Activation and route of administration both determine the ability of bone marrow-derived dendritic cells to accumulate in secondary lymphoid organs and prime CD8+ T cells against tumors.
Huck SP; Tang SC; Andrew KA; Yang J; Harper JL; Ronchese F
Cancer Immunol Immunother; 2008 Jan; 57(1):63-71. PubMed ID: 17609951
[TBL] [Abstract][Full Text] [Related]
7. Semi-allogeneic dendritic cells can induce antigen-specific T-cell activation, which is not enhanced by concurrent alloreactivity.
Wells JW; Cowled CJ; Darling D; Guinn BA; Farzaneh F; Noble A; Galea-Lauri J
Cancer Immunol Immunother; 2007 Dec; 56(12):1861-73. PubMed ID: 17487489
[TBL] [Abstract][Full Text] [Related]
8. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
[TBL] [Abstract][Full Text] [Related]
9. Critical role of Qa1b in the protection of mature dendritic cells from NK cell-mediated killing.
Persson CM; Assarsson E; Vahlne G; Brodin P; Chambers BJ
Scand J Immunol; 2008 Jan; 67(1):30-6. PubMed ID: 18028286
[TBL] [Abstract][Full Text] [Related]
10. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
11. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells.
Akazawa T; Ebihara T; Okuno M; Okuda Y; Shingai M; Tsujimura K; Takahashi T; Ikawa M; Okabe M; Inoue N; Okamoto-Tanaka M; Ishizaki H; Miyoshi J; Matsumoto M; Seya T
Proc Natl Acad Sci U S A; 2007 Jan; 104(1):252-7. PubMed ID: 17190817
[TBL] [Abstract][Full Text] [Related]
12. Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity.
He T; Tang C; Xu S; Moyana T; Xiang J
Cell Mol Immunol; 2007 Apr; 4(2):105-11. PubMed ID: 17484804
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase C-theta is required for NK cell activation and in vivo control of tumor progression.
Aguiló JI; Garaude J; Pardo J; Villalba M; Anel A
J Immunol; 2009 Feb; 182(4):1972-81. PubMed ID: 19201850
[TBL] [Abstract][Full Text] [Related]
14. Switching from a restricted to an effective CD4 T cell response by activating CD8+ murine dendritic cells with a Toll-like receptor 9 ligand.
Rizzitelli A; Vremec D; Villadangos JA; Mavaddat N; Wright MD; Shortman K
Eur J Immunol; 2005 Nov; 35(11):3209-20. PubMed ID: 16224811
[TBL] [Abstract][Full Text] [Related]
15. Melanoma cell necrosis facilitates transfer of specific sets of antigens onto MHC class II molecules of dendritic cells.
Röhn TA; Schadendorf D; Sun Y; Nguyen XD; Roeder D; Langen H; Vogt AB; Kropshofer H
Eur J Immunol; 2005 Oct; 35(10):2826-39. PubMed ID: 16163671
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments.
Kang TH; Lee JH; Bae HC; Noh KH; Kim JH; Song CK; Shin BC; Hung CF; Wu TC; Park JS; Kim TW
Immunol Lett; 2006 Aug; 106(2):126-34. PubMed ID: 16844231
[TBL] [Abstract][Full Text] [Related]
17. Induction of anti-tumor immunity by vaccination with dendritic cells pulsed with anti-CD44 IgG opsonized tumor cells.
Pilon-Thomas S; Verhaegen M; Kuhn L; Riker A; Mulé JJ
Cancer Immunol Immunother; 2006 Oct; 55(10):1238-46. PubMed ID: 16315029
[TBL] [Abstract][Full Text] [Related]
18. Natural killer dendritic cells are an intermediate of developing dendritic cells.
Chen L; Calomeni E; Wen J; Ozato K; Shen R; Gao JX
J Leukoc Biol; 2007 Jun; 81(6):1422-33. PubMed ID: 17332372
[TBL] [Abstract][Full Text] [Related]
19. A novel dendritic cell subset involved in tumor immunosurveillance.
Taieb J; Chaput N; Ménard C; Apetoh L; Ullrich E; Bonmort M; Péquignot M; Casares N; Terme M; Flament C; Opolon P; Lecluse Y; Métivier D; Tomasello E; Vivier E; Ghiringhelli F; Martin F; Klatzmann D; Poynard T; Tursz T; Raposo G; Yagita H; Ryffel B; Kroemer G; Zitvogel L
Nat Med; 2006 Feb; 12(2):214-9. PubMed ID: 16444265
[TBL] [Abstract][Full Text] [Related]
20. Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10.
Motomura Y; Senju S; Nakatsura T; Matsuyoshi H; Hirata S; Monji M; Komori H; Fukuma D; Baba H; Nishimura Y
Cancer Res; 2006 Feb; 66(4):2414-22. PubMed ID: 16489048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
